Sarepta Therapeutics Inc

NASDAQ:SRPTUnited States

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy (Duchenne), Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) disorders. It commercializes three products, such as EXONDYS 51 (eteplirsen) Injection, VYONDYS 53 (golodirsen) Injection and AMONDYS 45 (casimersen) Injection. These commercial products are indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51, exon 53 and exon 45 skipping. Its pipeline includes more than 40 programs at various stages of discovery, pre-clinical and clinical development.

Contact Information

Headquarters

215 1st St Ste 415CAMBRIDGE, MA, United States 02142-1213

Phone

617-274-4000

Fax

302-636-5454

Executives

Independent Chairwoman of the Board

M. Kathleen Behrens

President, Chief Executive Officer, Director

Douglas Ingram

Chief Financial Officer, Executive Vice President

Ian Estepan

Executive Vice President, Chief Scientific Officer, Head of R and D

Louise Rodino-Klapac

Senior Vice President, General Counsel, Corporate Secretary

Ryan Brown